Laure Stalnikiewicz

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>

Lionel Adès, Thomas Prébet, Aspasia Stamatoullas et al. · Haematologica · 2016 · 24 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma

Thomas Smol, Annika Dufour, Sabine Tricot et al. · Molecular Cytogenetics · 2017 · 20 citations · Full text

Medicine, Genetics, Oncology +17

Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM)

Lionel Adès, Thomas Prébet, Aspasia Stamatoullas et al. · Blood · 2010 · 17 citations

Medicine, Hematology, Oncology +17

SDF1/CXCL12 (−801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia

Stéphanie Poulain, Marjan Ertault, Xavier Leleu et al. · Leukemia Research · 2009 · 13 citations

Life Sciences, Genetics, Molecular Genetics +7

Prognostic factors in Waldenstrom's macroglobulinemia: Description of the complications during the evolution—preliminary results on 101 patients

Laure Stalnikiewicz, Isabelle Carrotte-Lefebvre, Laurence Detourmignies et al. · Seminars in Oncology · 2003 · 10 citations

Life Sciences, Hematology, Clinical Immunology +3